NCT04692324 Cerebrospinal Fluid Biomarkers for Brain Tumors
| NCT ID | NCT04692324 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Central Nervous System Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2021-01-14 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2021-01-14 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.
Eligibility Criteria
Inclusion Criteria: * Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures * Subjects must be 18 years of age or older Exclusion Criteria: * Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study * Pregnant women or women who may be pregnant are specifically excluded from study participation * Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available * Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded * Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded * Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access
Contact & Investigator
Terry C. Burns, MD, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT04692324 clinical trial?
This trial is open to participants of all sexes, studying Central Nervous System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04692324 currently recruiting?
Yes, NCT04692324 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT04692324 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT04692324 clinical trial?
NCT04692324 is sponsored by Mayo Clinic. The principal investigator is Terry C. Burns, MD, PhD at Mayo Clinic in Rochester. The trial plans to enroll 400 participants.